Uptake of Biosimilar Medicines in the South West
On 6th December 2017, the Senate Council deliberated:
To what extent and how should the transition to use of biosimilar medicines be prioritised to enable the provision of best value care in the NHS? Does the Clinical Senate support the uptake of biosimilar medicines at pace and how can their best practice use be maximised?
Download the recommendations here
Presentations:
Setting the Scene: Medicines Value Programme and Biosimilar Medicines Commissioning Framework – Stephen Brown, Regional Pharmacist, NHS England South
The MHRA Regulatory and Licensing Process – Anne Cook, Biologicals Quality Assessor, Licensing Division, Medicines and Healthcare Products Regulatory Authority
Pharmaceutical Perspective – Keiron Hughes, Head of Strategic Pricing, MSD Pharmaceuticals (Merck Sharp & Dohme Limited)
Infliximab Case Study – Dr Nick Kennedy, Consultant Gastroenterologist, RD&E
Patient Experience & Survey Findings: what is important to patients when changing medication? – Kevin Dixon, Chair of the South West Citizens’ Assembly
Pre-Reading:
Biosimilar Medicines Commissioning Framework
Agenda and Notes